GFACX
Price
$65.90
Change
+$0.75 (+1.15%)
Updated
Jan 17 closing price
Net Assets
306.54B
MSHOX
Price
$12.81
Change
+$0.06 (+0.47%)
Updated
Jan 17 closing price
Net Assets
4.86M
Ad is loading...

GFACX vs MSHOX

Header iconGFACX vs MSHOX Comparison
Open Charts GFACX vs MSHOXBanner chart's image
American Funds Growth Fund of Amer C
Price$65.90
Change+$0.75 (+1.15%)
VolumeN/A
Net Assets306.54B
Morgan Stanley Inst Permanence C
Price$12.81
Change+$0.06 (+0.47%)
VolumeN/A
Net Assets4.86M
GFACX vs MSHOX Comparison Chart
Loading...
View a ticker or compare two or three
VS
GFACX vs. MSHOX commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GFACX is a StrongBuy and MSHOX is a Sell.

Ad is loading...
FUNDAMENTALS
Fundamentals
GFACX has more cash in the bank: 307B vs. MSHOX (4.86M). GFACX (0.00) and MSHOX (0.00) have matching dividends . GFACX was incepted earlier than MSHOX: GFACX (24 years) vs MSHOX (5 years). MSHOX is a more actively managed with annual turnover of: 100.00 vs. GFACX (31.00). GFACX has a lower initial minimum investment than MSHOX: GFACX (250) vs MSHOX (1000). GFACX annual gain was more profitable for investors over the last year : 19.88 vs. MSHOX (8.17).
GFACXMSHOXGFACX / MSHOX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence24 years5 years-
Gain YTD3.3564.91468%
Front LoadN/AN/A-
Min. Initial Investment250100025%
Min. Initial Investment IRAN/AN/A-
Net Assets307B4.86M6,319,473%
Annual Yield % from dividends0.000.00-
Returns for 1 year19.888.17243%
Returns for 3 years7.801.88415%
Returns for 5 years36.07N/A-
Returns for 10 years65.62N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ARL15.781.93
+13.94%
American Realty Investors
ECOR15.900.20
+1.27%
electroCore
GIS59.630.47
+0.79%
General Mills
FROG32.75-0.03
-0.09%
JFrog Ltd
COLL33.35-0.11
-0.33%
Collegium Pharmaceutical